Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Temozolomide and Other Alkylating Agents in Glioblastoma Therapy.

Strobel H, Baisch T, Fitzel R, Schilberg K, Siegelin MD, Karpel-Massler G, Debatin KM, Westhoff MA.

Biomedicines. 2019 Sep 9;7(3). pii: E69. doi: 10.3390/biomedicines7030069. Review.

2.

Activation of LXRβ inhibits tumor respiration and is synthetically lethal with Bcl-xL inhibition.

Nguyen TTT, Ishida CT, Shang E, Shu C, Torrini C, Zhang Y, Bianchetti E, Sanchez-Quintero MJ, Kleiner G, Quinzii CM, Westhoff MA, Karpel-Massler G, Canoll P, Siegelin MD.

EMBO Mol Med. 2019 Aug 29:e10769. doi: 10.15252/emmm.201910769. [Epub ahead of print]

3.

Inhibition of Gap Junctions Sensitizes Primary Glioblastoma Cells for Temozolomide.

Potthoff AL, Heiland DH, Evert BO, Almeida FR, Behringer SP, Dolf A, Güresir Á, Güresir E, Joseph K, Pietsch T, Schuss P, Herrlinger U, Westhoff MA, Vatter H, Waha A, Schneider M.

Cancers (Basel). 2019 Jun 20;11(6). pii: E858. doi: 10.3390/cancers11060858.

4.

Bcl-2/Bcl-xL inhibition predominantly synergistically enhances the anti-neoplastic activity of a low-dose CUSP9 repurposed drug regime against glioblastoma.

Halatsch ME, Kast RE, Dwucet A, Hlavac M, Heiland T, Westhoff MA, Debatin KM, Wirtz CR, Siegelin MD, Karpel-Massler G.

Br J Pharmacol. 2019 Sep;176(18):3681-3694. doi: 10.1111/bph.14773. Epub 2019 Jul 30.

PMID:
31222722
5.

Combined inhibition of RAC1 and Bcl-2/Bcl-xL synergistically induces glioblastoma cell death through down-regulation of the Usp9X/Mcl-1 axis.

Hlavac M, Dwucet A, Kast RE, Engelke J, Westhoff MA, Siegelin MD, Debatin KM, Wirtz CR, Halatsch ME, Karpel-Massler G.

Cell Oncol (Dordr). 2019 Jun;42(3):287-301. doi: 10.1007/s13402-019-00425-3. Epub 2019 Mar 11.

PMID:
30859392
6.

FBXW7 mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL.

Close V, Close W, Kugler SJ, Reichenzeller M, Yosifov DY, Bloehdorn J, Pan L, Tausch E, Westhoff MA, Döhner H, Stilgenbauer S, Oswald F, Mertens D.

Blood. 2019 Feb 21;133(8):830-839. doi: 10.1182/blood-2018-09-874529. Epub 2018 Dec 3.

PMID:
30510140
7.

Viability of glioblastoma stem cells is effectively reduced by diisothiocyanate-derived mercapturic acids.

Cwiklowska K, Westhoff MA, Freisinger S, Dwucet A, Halatsch ME, Knippschild U, Debatin KM, Schirmbeck R, Winiarski L, Oleksyszyn J, Wirtz CR, Burster T.

Oncol Lett. 2018 Nov;16(5):6181-6187. doi: 10.3892/ol.2018.9347. Epub 2018 Aug 21.

8.

Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems.

Shang E, Zhang Y, Shu C, Ishida CT, Bianchetti E, Westhoff MA, Karpel-Massler G, Siegelin MD.

Sci Rep. 2018 Oct 18;8(1):15383. doi: 10.1038/s41598-018-33784-2.

9.

Precision medicine in pediatric oncology.

Burdach SEG, Westhoff MA, Steinhauser MF, Debatin KM.

Mol Cell Pediatr. 2018 Aug 31;5(1):6. doi: 10.1186/s40348-018-0084-3. Review.

10.

Inhibition of PI3K signalling increases the efficiency of radiotherapy in glioblastoma cells.

Hasslacher S, Schneele L, Stroh S, Langhans J, Zeiler K, Kattner P, Karpel-Massler G, Siegelin MD, Schneider M, Zhou S, Grunert M, Halatsch ME, Nonnenmacher L, Debatin KM, Westhoff MA.

Int J Oncol. 2018 Nov;53(5):1881-1896. doi: 10.3892/ijo.2018.4528. Epub 2018 Aug 16.

11.

Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma.

Ishida CT, Zhang Y, Bianchetti E, Shu C, Nguyen TTT, Kleiner G, Sanchez-Quintero MJ, Quinzii CM, Westhoff MA, Karpel-Massler G, Prabhu VV, Allen JE, Siegelin MD.

Clin Cancer Res. 2018 Nov 1;24(21):5392-5406. doi: 10.1158/1078-0432.CCR-18-1040. Epub 2018 Jul 23.

PMID:
30037819
12.

Radiation and Brain Tumors: An Overview.

Grunert M, Kassubek R, Danz B, Klemenz B, Hasslacher S, Stroh S, Schneele L, Langhans J, Ströbele S, Barry SE, Zhou S, Debatin KM, Westhoff MA.

Crit Rev Oncog. 2018;23(1-2):119-138. doi: 10.1615/CritRevOncog.2018025927. Review.

PMID:
29953371
13.

Combined HDAC and Bromodomain Protein Inhibition Reprograms Tumor Cell Metabolism and Elicits Synthetic Lethality in Glioblastoma.

Zhang Y, Ishida CT, Ishida W, Lo SL, Zhao J, Shu C, Bianchetti E, Kleiner G, Sanchez-Quintero MJ, Quinzii CM, Westhoff MA, Karpel-Massler G, Canoll P, Siegelin MD.

Clin Cancer Res. 2018 Aug 15;24(16):3941-3954. doi: 10.1158/1078-0432.CCR-18-0260. Epub 2018 May 15.

14.

Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma.

Zhang Y, Ishida CT, Shu C, Kleiner G, Sanchez-Quintero MJ, Bianchetti E, Quinzii CM, Westhoff MA, Karpel-Massler G, Siegelin MD.

Sci Rep. 2018 May 9;8(1):7373. doi: 10.1038/s41598-018-25802-0.

15.

Blocking distinct interactions between Glioblastoma cells and their tissue microenvironment: A novel multi-targeted therapeutic approach.

Mettang M, Meyer-Pannwitt V, Karpel-Massler G, Zhou S, Carragher NO, Föhr KJ, Baumann B, Nonnenmacher L, Enzenmüller S, Dahlhaus M, Siegelin MD, Stroh S, Mertens D, Fischer-Posovszky P, Schneider EM, Halatsch ME, Debatin KM, Westhoff MA.

Sci Rep. 2018 Apr 3;8(1):5527. doi: 10.1038/s41598-018-23592-z.

16.

Cell death-based treatment of childhood cancer.

Westhoff MA, Marschall N, Grunert M, Karpel-Massler G, Burdach S, Debatin KM.

Cell Death Dis. 2018 Jan 25;9(2):116. doi: 10.1038/s41419-017-0062-z. Review.

17.

The effects of PI3K-mediated signalling on glioblastoma cell behaviour.

Langhans J, Schneele L, Trenkler N, von Bandemer H, Nonnenmacher L, Karpel-Massler G, Siegelin MD, Zhou S, Halatsch ME, Debatin KM, Westhoff MA.

Oncogenesis. 2017 Nov 29;6(11):398. doi: 10.1038/s41389-017-0004-8.

18.

Anti-glioma Activity of Dapsone and Its Enhancement by Synthetic Chemical Modification.

Karpel-Massler G, Kast RE, Siegelin MD, Dwucet A, Schneider E, Westhoff MA, Wirtz CR, Chen XY, Halatsch ME, Bolm C.

Neurochem Res. 2017 Dec;42(12):3382-3389. doi: 10.1007/s11064-017-2378-6. Epub 2017 Aug 29.

PMID:
28852934
19.

Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma.

Karpel-Massler G, Ishida CT, Zhang Y, Halatsch ME, Westhoff MA, Siegelin MD.

Expert Opin Drug Discov. 2017 Oct;12(10):1031-1040. doi: 10.1080/17460441.2017.1356286. Epub 2017 Jul 20. Review.

20.

Cerebral Microstructural Alterations after Radiation Therapy in High-Grade Glioma: A Diffusion Tensor Imaging-Based Study.

Kassubek R, Gorges M, Westhoff MA, Ludolph AC, Kassubek J, Müller HP.

Front Neurol. 2017 Jun 15;8:286. doi: 10.3389/fneur.2017.00286. eCollection 2017.

21.

Abstracts of the 52nd Workshop for Pediatric Research : Frankfurt, Germany. 27-28 October 2016.

van den Bruck R, Weil PP, Ziegenhals T, Schreiner P, Juranek S, Gödde D, Vogel S, Schuster F, Orth V, Dörner J, Pembaur D, Röper M, Störkel S, Zirngibl H, Wirth S, Jenke ACW, Postberg J, Boy N, Heringer J, Haege G, Glahn EM, Hoffmann GF, Garbade SF, Burgard P, Kölker S, Chao CM, Yahya F, Moiseenko A, Shrestha A, Ahmadvand N, Quantius J, Wilhelm J, El-Agha E, Zimmer KP, Bellusci S, Staufner C, Kölker S, Prokisch H, Hoffmann GF, Seeliger S, Müller M, Hippe A, Steinkraus H, Wauer R, Lachmann B, Hofmann SR, Hedrich CM, Zierk J, Arzideh F, Haeckel R, Rascher W, Rauh M, Metzler M, Thieme S, Bandoła J, Richter C, Ryser M, Jamal A, Ashton MP, von Bonin M, Kuhn M, Hedrich CM, Bonifacio E, Berner R, Brenner S, Hammersen J, Has C, Naumann-Bartsch N, Stachel D, Kiritsi D, Söder S, Tardieu M, Metzler M, Bruckner-Tuderman L, Schneider H, Bohne F, Langer D, Cencic R, Eggermann T, Zechner U, Pelletier J, Zepp F, Enklaar T, Prawitt D, Pech M, Weckmann M, Heinsen FA, Franke A, Happle C, Dittrich AM, Hansen G, Fuchs O, von Mutius E, Oliver BG, Kopp MV, Paret C, Russo A, Theruvath J, Keller B, El Malki K, Lehmann N, Wingerter A, Neu MA, Aslihan GA, Wagner W, Sommer C, Pietsch T, Seidmann L, Faber J, Schreiner F, Ackermann M, Michalik M, Rother E, Bilkei-Gorzo A, Racz I, Bindila L, Lutz B, Dötsch J, Zimmer A, Woelfle J, Fischer HS, Ullrich TL, Bührer C, Czernik C, Schmalisch G, Stein R, Hofmann SR, Hagenbuchner J, Kiechl-Kohlendorfer U, Obexer P, Ausserlechner MJ, Loges NT, Frommer AT, Wallmeier J, Omran H, Öner-Sieben S, Gimpfl M, Rozman J, Irmler M, Beckers J, De Angelis MH, Roscher A, Wolf E, Ensenauer R, Nemes K, Frühwald M, Hasselblatt M, Siebert R, Kordes U, Kool M, Wang H, Hardy H, Refai O, Barwick KES, Zimmerman HH, Weis J, Baple EL, Crosby AH, Cirak S, Hellmuth C, Uhl O, Standl M, Heinrich J, Thiering E, Koletzko B, Blümel L, Kerl K, Picard D, Frühwald MC, Liebau MC, Reifenberger G, Borkhardt A, Hasselblatt M, Remke M, Tews D, Wabitsch M, Fischer-Posovszky P, Westhoff MA, Nonnenmacher L, Langhans J, Schneele L, Trenkler N, Debatin KM.

Mol Cell Pediatr. 2017 May;4(Suppl 1):5. doi: 10.1186/s40348-017-0071-0. No abstract available.

22.

BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.

Ishida CT, Bianchetti E, Shu C, Halatsch ME, Westhoff MA, Karpel-Massler G, Siegelin MD.

Oncotarget. 2017 May 2;8(18):29558-29573. doi: 10.18632/oncotarget.16365.

23.

Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma.

Ishida CT, Shu C, Halatsch ME, Westhoff MA, Altieri DC, Karpel-Massler G, Siegelin MD.

Oncotarget. 2017 Jun 6;8(23):37140-37153. doi: 10.18632/oncotarget.16202.

24.

Cancer stem cells: The potential role of autophagy, proteolysis, and cathepsins in glioblastoma stem cells.

Bischof J, Westhoff MA, Wagner JE, Halatsch ME, Trentmann S, Knippschild U, Wirtz CR, Burster T.

Tumour Biol. 2017 Mar;39(3):1010428317692227. doi: 10.1177/1010428317692227. Review.

PMID:
28347245
25.

Simultaneous Interference with HER1/EGFR and RAC1 Signaling Drives Cytostasis and Suppression of Survivin in Human Glioma Cells in Vitro.

Karpel-Massler G, Westhoff MA, Kast RE, Dwucet A, Karpel-Massler S, Nonnenmacher L, Siegelin MD, Wirtz CR, Debatin KM, Halatsch ME.

Neurochem Res. 2017 May;42(5):1543-1554. doi: 10.1007/s11064-017-2213-0. Epub 2017 Mar 7.

PMID:
28271323
26.

Cell Death Induction in Cancer Therapy - Past, Present, and Future.

Nonnenmacher L, Hasslacher S, Zimmermann J, Karpel-Massler G, La Ferla-Brühl K, Barry SE, Burster T, Siegelin MD, Brühl O, Halatsch ME, Debatin KM, Westhoff MA.

Crit Rev Oncog. 2016;21(3-4):253-267. Review.

PMID:
27915975
27.

Exogenous cathepsin G upregulates cell surface MHC class I molecules on immune and glioblastoma cells.

Giese M, Turiello N, Molenda N, Palesch D, Meid A, Schroeder R, Basilico P, Benarafa C, Halatsch ME, Zimecki M, Westhoff MA, Wirtz CR, Burster T.

Oncotarget. 2016 Nov 15;7(46):74602-74611. doi: 10.18632/oncotarget.12980.

28.

Immune phenotypes predict survival in patients with glioblastoma multiforme.

Mostafa H, Pala A, Högel J, Hlavac M, Dietrich E, Westhoff MA, Nonnenmacher L, Burster T, Georgieff M, Wirtz CR, Schneider EM.

J Hematol Oncol. 2016 Sep 1;9(1):77. doi: 10.1186/s13045-016-0272-3.

29.

Novel Approaches to Apoptosis-Inducing Therapies.

Westhoff MA, Marschall N, Debatin KM.

Adv Exp Med Biol. 2016;930:173-204. doi: 10.1007/978-3-319-39406-0_8. Review.

PMID:
27558822
30.

Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo.

Karpel-Massler G, Ramani D, Shu C, Halatsch ME, Westhoff MA, Bruce JN, Canoll P, Siegelin MD.

Oncotarget. 2016 Jun 7;7(23):33512-28. doi: 10.18632/oncotarget.9257.

31.

Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo.

Karpel-Massler G, Banu MA, Shu C, Halatsch ME, Westhoff MA, Bruce JN, Canoll P, Siegelin MD.

Oncotarget. 2016 Mar 15;7(11):12791-805. doi: 10.18632/oncotarget.7302.

32.

Cathepsin G-mediated proteolytic degradation of MHC class I molecules to facilitate immune detection of human glioblastoma cells.

Palesch D, Wagner J, Meid A, Molenda N, Sienczyk M, Burkhardt J, Münch J, Prokop L, Stevanovic S, Westhoff MA, Halatsch ME, Wirtz CR, Zimecki M, Burster T.

Cancer Immunol Immunother. 2016 Mar;65(3):283-91. doi: 10.1007/s00262-016-1798-5. Epub 2016 Feb 2.

PMID:
26837514
33.

Cancer therapy: know your enemy?

Westhoff MA, Brühl O, Debatin KM.

Mol Cell Pediatr. 2014 Dec;1(1):10. doi: 10.1186/s40348-014-0010-2. Epub 2014 Oct 31.

34.

A paired comparison between glioblastoma "stem cells" and differentiated cells.

Schneider M, Ströbele S, Nonnenmacher L, Siegelin MD, Tepper M, Stroh S, Hasslacher S, Enzenmüller S, Strauss G, Baumann B, Karpel-Massler G, Westhoff MA, Debatin KM, Halatsch ME.

Int J Cancer. 2016 Apr 1;138(7):1709-18. doi: 10.1002/ijc.29908. Epub 2015 Nov 17.

35.

TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.

Karpel-Massler G, Bâ M, Shu C, Halatsch ME, Westhoff MA, Bruce JN, Canoll P, Siegelin MD.

Oncotarget. 2015 Nov 3;6(34):36456-71. doi: 10.18632/oncotarget.5505.

36.

A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.

Ströbele S, Schneider M, Schneele L, Siegelin MD, Nonnenmacher L, Zhou S, Karpel-Massler G, Westhoff MA, Halatsch ME, Debatin KM.

PLoS One. 2015 Jun 29;10(6):e0131670. doi: 10.1371/journal.pone.0131670. eCollection 2015. Erratum in: PLoS One. 2015;10(7):e0134770. Karpel-Massle, Georg [corrected to Karpel-Massler, Georg].

37.

Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo.

Karpel-Massler G, Shu C, Chau L, Banu M, Halatsch ME, Westhoff MA, Ramirez Y, Ross AH, Bruce JN, Canoll P, Siegelin MD.

Oncotarget. 2015 Jun 10;6(16):14507-21.

38.

PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma.

Karpel-Massler G, Pareja F, Aimé P, Shu C, Chau L, Westhoff MA, Halatsch ME, Crary JF, Canoll P, Siegelin MD.

PLoS One. 2014 Dec 22;9(12):e114583. doi: 10.1371/journal.pone.0114583. eCollection 2014.

39.

Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect.

Karpel-Massler G, Kast RE, Westhoff MA, Dwucet A, Welscher N, Nonnenmacher L, Hlavac M, Siegelin MD, Wirtz CR, Debatin KM, Halatsch ME.

J Neurooncol. 2015 Mar;122(1):21-33. doi: 10.1007/s11060-014-1688-7. Epub 2014 Dec 19.

PMID:
25524815
40.

KIT mutations in primary mediastinal B-cell lymphoma.

Nagel PD, Stenzinger A, Feld FM, Herrmann MD, Brüderlein S, Barth TF, Marienfeld R, Endris V, Weichert W, Debatin KM, Westhoff MA, Lessel D, Möller P, Lennerz JK.

Blood Cancer J. 2014 Aug 22;4:e241. doi: 10.1038/bcj.2014.61. No abstract available.

41.

RIST: a potent new combination therapy for glioblastoma.

Nonnenmacher L, Westhoff MA, Fulda S, Karpel-Massler G, Halatsch ME, Engelke J, Simmet T, Corbacioglu S, Debatin KM.

Int J Cancer. 2015 Feb 15;136(4):E173-87. doi: 10.1002/ijc.29138. Epub 2014 Sep 1.

42.

Killing me softly--future challenges in apoptosis research.

Westhoff MA, Brühl O, Nonnenmacher L, Karpel-Massler G, Debatin KM.

Int J Mol Sci. 2014 Mar 3;15(3):3746-67. doi: 10.3390/ijms15033746. Review.

43.

Artesunate enhances the antiproliferative effect of temozolomide on U87MG and A172 glioblastoma cell lines.

Karpel-Massler G, Westhoff MA, Kast RE, Dwucet A, Nonnenmacher L, Wirtz CR, Debatin KM, Halatsch ME.

Anticancer Agents Med Chem. 2014 Feb;14(2):313-8.

PMID:
24506460
44.

Sequential dosing in chemosensitization: targeting the PI3K/Akt/mTOR pathway in neuroblastoma.

Westhoff MA, Faham N, Marx D, Nonnenmacher L, Jennewein C, Enzenmüller S, Gonzalez P, Fulda S, Debatin KM.

PLoS One. 2013 Dec 31;8(12):e83128. doi: 10.1371/journal.pone.0083128. eCollection 2013.

45.

A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy.

Westhoff MA, Karpel-Massler G, Brühl O, Enzenmüller S, La Ferla-Brühl K, Siegelin MD, Nonnenmacher L, Debatin KM.

Mol Cell Ther. 2014 Oct 27;2:32. doi: 10.1186/2052-8426-2-32. eCollection 2014. Review.

46.

Phosphoinositide 3-kinases upregulate system xc(-) via eukaryotic initiation factor 2α and activating transcription factor 4 - A pathway active in glioblastomas and epilepsy.

Lewerenz J, Baxter P, Kassubek R, Albrecht P, Van Liefferinge J, Westhoff MA, Halatsch ME, Karpel-Massler G, Meakin PJ, Hayes JD, Aronica E, Smolders I, Ludolph AC, Methner A, Conrad M, Massie A, Hardingham GE, Maher P.

Antioxid Redox Signal. 2014 Jun 20;20(18):2907-22. doi: 10.1089/ars.2013.5455. Epub 2014 Feb 6.

47.

Transitory dasatinib-resistant states in KIT(mut) t(8;21) acute myeloid leukemia cells correlate with altered KIT expression.

Herrmann MD, Lennerz JK, Bullinger L, Bartholomae S, Holzmann K, Westhoff MA, Corbacioglu S, Debatin KM.

Exp Hematol. 2014 Feb;42(2):90-100. doi: 10.1016/j.exphem.2013.10.006. Epub 2013 Nov 6.

PMID:
24211243
48.

Inhibition of NF-κB signaling ablates the invasive phenotype of glioblastoma.

Westhoff MA, Zhou S, Nonnenmacher L, Karpel-Massler G, Jennewein C, Schneider M, Halatsch ME, Carragher NO, Baumann B, Krause A, Simmet T, Bachem MG, Wirtz CR, Debatin KM.

Mol Cancer Res. 2013 Dec;11(12):1611-23. doi: 10.1158/1541-7786.MCR-13-0435-T. Epub 2013 Oct 21.

49.

Combined inhibition of HER1/EGFR and RAC1 results in a synergistic antiproliferative effect on established and primary cultured human glioblastoma cells.

Karpel-Massler G, Westhoff MA, Zhou S, Nonnenmacher L, Dwucet A, Kast RE, Bachem MG, Wirtz CR, Debatin KM, Halatsch ME.

Mol Cancer Ther. 2013 Sep;12(9):1783-95. doi: 10.1158/1535-7163.MCT-13-0052. Epub 2013 Jul 5.

50.

Antiviral vaccines license T cell responses by suppressing granzyme B levels in human plasmacytoid dendritic cells.

Fabricius D, Nußbaum B, Busch D, Panitz V, Mandel B, Vollmer A, Westhoff MA, Kaltenmeier C, Lunov O, Tron K, Nienhaus GU, Jahrsdörfer B, Debatin KM.

J Immunol. 2013 Aug 1;191(3):1144-53. doi: 10.4049/jimmunol.1203479. Epub 2013 Jun 19.

Supplemental Content

Loading ...
Support Center